Sandilands Euan A, Crowe Jane, Cuthbert Hayley, Jenkins Paul J, Johnston Neil R, Eddleston Michael, Bateman D Nicholas, Webb David J
NPIS (Edinburgh), Scottish Poisons Information Bureau, Royal Infirmary of Edinburgh, Edinburgh, UK.
Br J Clin Pharmacol. 2013 Nov;76(5):699-707. doi: 10.1111/bcp.12110.
To investigate the mechanism of action of intra-arterial histamine in the human forearm vasculature.
Three studies were conducted to assess changes in forearm blood flow (FBF) using venous occlusion plethysmography in response to intra-brachial histamine. First, the dose-response was investigated by assessing FBF throughout a dose-escalating histamine infusion. Next, histamine was infused at a constant dose to assess acute tolerance. Finally, a four way, double-blind, randomized, placebo-controlled crossover study was conducted to assess FBF response to histamine in the presence of H1 - and H2 -receptor antagonists. Flare and itch were assessed in all studies.
Histamine caused a dose-dependent increase in FBF, greatest with the highest dose (30 nmol min(-1) ) infused [mean (SEM) infused arm vs. control: 26.8 (5.3) vs. 2.6 ml min(-1) 100 ml(-1) ; P < 0.0001]. Dose-dependent flare and itch were demonstrated. Acute tolerance was not observed, with an increased FBF persisting throughout the infusion period. H2 -receptor antagonism significantly reduced FBF (mean (95% CI) difference from placebo at 30 nmol min(-1) histamine: -11.9 ml min(-1) 100 ml(-1) (-4.0, -19.8), P < 0.0001) and flare (mean (95% CI) difference from placebo: -403.7 cm(2) (-231.4, 576.0), P < 0.0001). No reduction in FBF or flare was observed in response to the H1 -receptor antagonist. Itch was unaffected by the treatments. Histamine did not stimulate vascular release of tissue plasminogen activator or von Willebrand factor.
Histamine causes dose-dependent vasodilatation, flare and itch in the human forearm. H2 -receptors are important in this process. Our results support further exploration of combined H1 - and H2 -receptor antagonist therapy in acute allergic syndromes.
研究动脉内注射组胺在人体前臂血管系统中的作用机制。
进行了三项研究,采用静脉阻断体积描记法评估前臂血流量(FBF)对肱动脉注射组胺的反应。首先,通过在组胺输注剂量递增过程中评估FBF来研究剂量反应。其次,以恒定剂量输注组胺以评估急性耐受性。最后,进行了一项四组、双盲、随机、安慰剂对照的交叉研究,以评估在存在H1和H2受体拮抗剂的情况下FBF对组胺的反应。在所有研究中均评估了潮红和瘙痒。
组胺导致FBF呈剂量依赖性增加,在输注最高剂量(30 nmol·min⁻¹)时增加最为明显[输注侧手臂平均值(标准误)与对照相比:26.8(5.3)对2.6 ml·min⁻¹·100 ml⁻¹;P < 0.0001]。呈现出剂量依赖性的潮红和瘙痒。未观察到急性耐受性,在整个输注期间FBF持续增加。H2受体拮抗作用显著降低了FBF(在组胺剂量为30 nmol·min⁻¹时,与安慰剂的平均差值(95%可信区间):-11.9 ml·min⁻¹·100 ml⁻¹(-4.0,-19.8),P < 0.0001)和潮红(与安慰剂的平均差值(95%可信区间):-403.7 cm²(-231.4,576.0),P < 0.0001)。未观察到H1受体拮抗剂对FBF或潮红有降低作用。瘙痒不受这些治疗的影响。组胺未刺激血管释放组织纤溶酶原激活剂或血管性血友病因子。
组胺在人体前臂引起剂量依赖性血管舒张、潮红和瘙痒。H2受体在这一过程中起重要作用。我们的结果支持在急性过敏综合征中进一步探索联合H1和H2受体拮抗剂治疗。